Assembly Biosciences (ASMB) Price & Analysis

Compare

566 Followers

ASMB Stock Chart & Stats

$29.45

-$0.45(-2.59%)

At close: Jan 08 4:00 PM EST

$29.45

-$0.45(-2.59%)

Day’s Range― - ―

52-Week Range$7.75 - $29.40

Previous CloseN/A

Volume7.37K

Average Volume (3M)161.99K

Market Cap

$452.49M

Enterprise Value$66.63M

Total Cash (Recent Filing)$74.98M

Total Debt (Recent Filing)$2.88M

Price to Earnings (P/E)―

Beta1.22

Next Earnings

Nov 06, 2025

EPS Estimate

-0.82

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.33

Shares Outstanding15,560,009

10 Day Avg. Volume146,094

30 Day Avg. Volume161,991

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.15

Enterprise Value/Revenue2.82

Enterprise Value/Gross Profit2.82

Enterprise Value/Ebitda-1.53

Forecast

1Y Price Target

$39.00

Price Target Upside32.43% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

Bulls Say, Bears Say

Bulls Say

Drug DevelopmentInterim Phase 1b data reinforce ABI-5366’s best-in-class potential and support advancement toward Phase 2.

Market OpportunityWith ~800,000 U.S. patients on suppressive therapy and dissatisfaction with daily generics, a once-monthly oral could redefine treatment paradigms and support a ~$1B U.S. market opportunity.

Strategic PartnershipsA committed strategic partner, deep antiviral expertise, and multiple upcoming catalysts position Assembly to generate significant upside from two high-value infectious disease franchises.

Bears Say

Clinical TrialsBoth programs are advancing through Phase 1 trials with encouraging interim data, demonstrating favorable safety and efficacy results.

Assembly Biosciences News

Assembly Biosciences files to sell 6.98M shares of commons stock for holders

16:22 EDT Assembly Biosciences (ASMB) files to sell 6.98M shares of commons stock for holders Published first on...

4d ago

ASMB

Assembly Biosciences presents interim Phase 1b data for ABI-5366

Assembly Biosciences (ASMB) announced that interim Phase 1b clinical data for its long-acting herpes simplex virus helicase-primase inhibitor...

8d ago

ASMB

Amazon upgraded, Adobe downgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

24d ago

Assembly Biosciences initiated with an Outperform at Citizens JMP

Citizens JMP analyst Roy Buchanan initiated coverage of Assembly Biosciences (ASMB) with an Outperform rating and $38 price...

24d ago

ASMB

Promising Phase 1b Results for ABI-5366 Drive Buy Rating for Assembly Biosciences

Analyst Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Assembly Biosciences and keeping the price target...

4d ago

ASMB

Assembly Biosciences price target raised to $39 from $31 at Guggenheim

Guggenheim raised the firm’s price target on Assembly Biosciences (ASMB) to $39 from $31 and keeps a Buy...

1M ago

ASMB

Four new option listings and one option delisting on August 27th

New option listings for August 27th include Assembly Biosciences (ASMB), CEA Industries Inc (BNC), Dynamix Corp (ETHM), and...

2M ago

BNC

ASMB

Assembly Biosciences assumed with a Buy at H.C. Wainwright

H.C. Wainwright analyst Patrick Trucchio assumed coverage of Assembly Biosciences (ASMB) with a Buy rating and $50 price...

2M ago

ASMB

Assembly Biosciences Completes $175 Million Equity Financing

Assembly Biosciences ( ($ASMB) ) just unveiled an announcement. On August 8, 2025, Assembly Biosciences announced the pricing...

2M ago

ASMB

Assembly Biosciences Announces Positive Phase 1b Results

Assembly Biosciences ( ($ASMB) ) has provided an announcement. On August 8, 2025, Assembly Biosciences announced positive interim...

2M ago

ASMB

Assembly Biosciences announces pricing of $175M in equity financings

Assembly Biosciences (ASMB) announced the pricing of an underwritten, registered offering of an aggregate of 5,591,840 shares of...

2M ago

ASMB

Assembly Biosciences reports interim results from phase 1b study of ABI-5366

Assembly Biosciences (ASMB) announced positive interim antiviral activity, clinical outcomes, safety and pharmacokinetic results from a Phase 1b...

2M ago

ASMB

GILD

Assembly Biosciences Reports Q2 2025 Progress and Financials

Assembly Biosciences Inc ( ($ASMB) ) has released its Q2 earnings. Here is a breakdown of the information...

2M ago

ASMB

Assembly Biosciences Reports Interim Results for ABI-6250

An update from Assembly Biosciences ( ($ASMB) ) is now available. On August 6, 2025, Assembly Biosciences announced...

2M ago

ASMB

ASMB FAQ

What was Assembly Biosciences’s price range in the past 12 months?

Assembly Biosciences lowest stock price was $7.75 and its highest was $29.40 in the past 12 months.

What is Assembly Biosciences’s market cap?

Assembly Biosciences’s market cap is $452.49M.

When is Assembly Biosciences’s upcoming earnings report date?

Assembly Biosciences’s upcoming earnings report date is Nov 06, 2025 which is in 19 days.

How were Assembly Biosciences’s earnings last quarter?

Assembly Biosciences released its earnings results on Aug 06, 2025. The company reported -$1.33 earnings per share for the quarter, beating the consensus estimate of -$1.73 by $0.4.

Is Assembly Biosciences overvalued?

According to Wall Street analysts Assembly Biosciences’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Assembly Biosciences pay dividends?

Assembly Biosciences does not currently pay dividends.

What is Assembly Biosciences’s EPS estimate?

Assembly Biosciences’s EPS estimate is -0.82.

How many shares outstanding does Assembly Biosciences have?

Assembly Biosciences has 15,560,009 shares outstanding.

What happened to Assembly Biosciences’s price movement after its last earnings report?

Assembly Biosciences reported an EPS of -$1.33 in its last earnings report, beating expectations of -$1.73. Following the earnings report the stock price went up 9.213%.

Which hedge fund is a major shareholder of Assembly Biosciences?

Currently, no hedge funds are holding shares in ASMB

Assembly Biosciences Stock Smart Score

Neutral

Fundamentals

Return on Equity

-147.64%

Trailing 12-Months

Asset Growth

-29.95%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Assembly Biosciences

Assembly Biosciences, Inc. is a biotechnology company focused on developing innovative therapies for the treatment of viral infections, particularly hepatitis B virus (HBV) and other liver diseases. The company operates in the biopharmaceutical sector and leverages its proprietary technology platforms to create novel antiviral therapeutics. Assembly Biosciences aims to address significant unmet medical needs through its core products, which include small molecule antiviral candidates and therapeutic vaccines.

Assembly Biosciences (ASMB) Earnings & Revenues

Historic Earnings Reports

ASMB Stock 12 Month Forecast

Average Price Target

$39.00

▲(32.43% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"10":"$10","51":"$51","20.25":"$20.3","30.5":"$30.5","40.75":"$40.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":50,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$50.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":39,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$39.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":29,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$29.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[10,20.25,30.5,40.75,51],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Mar<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.61,26.563076923076924,28.516153846153845,30.46923076923077,32.42230769230769,34.37538461538462,36.32846153846154,38.28153846153846,40.23461538461538,42.18769230769231,44.14076923076923,46.09384615384616,48.04692307692308,{"y":50,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.61,25.716923076923077,26.823846153846155,27.93076923076923,29.037692307692307,30.144615384615385,31.25153846153846,32.35846153846154,33.465384615384615,34.57230769230769,35.67923076923077,36.786153846153844,37.89307692307692,{"y":39,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.61,24.947692307692307,25.285384615384615,25.623076923076923,25.96076923076923,26.298461538461538,26.636153846153846,26.973846153846154,27.31153846153846,27.64923076923077,27.986923076923077,28.324615384615385,28.662307692307692,{"y":29,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":13.27,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.15,"date":1717200000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":14.35,"date":1722470400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":16.26,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.89,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.75,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.88,"date":1740787200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":11.44,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.4,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.73,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.4,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.13,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.61,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >